Industry
Cell and Gene Therapy market research
Research on treatment centre readiness, logistics and payer models for advanced therapies.
HealthcareMarketResearch runs cell and gene therapy market research for global leaders, challengers and investors. Our 5,000+ researchers include practising clinicians, procurement leaders, payers and former executives from the cell and gene therapy industry.
Studies combine expert calls, qualitative interviews and quantitative surveys, so you can size the opportunity, understand stakeholders and plan go-to-market with confidence.
Topics we research
- Treatment centres
- Outcomes-based pricing
- Manufacturing
- Patient eligibility
Relevant services
At a glance
Cell and Gene Therapy market research at a glance
The audiences, methods and timelines a typical cell and gene therapy study runs on.
- Audiences
- Treatment centre directors, transplant and cell therapy physicians, apheresis and cell processing leads, hospital pharmacists, qualified person and QA leads, payers assessing outcomes-based models
- Typical methods
- Treatment centre readiness interviews, expert calls with transplant and cell therapy teams, logistics and cold chain interviews, payer contracting research
- Research focus
- treatment centres · outcomes-based pricing · manufacturing · patient eligibility
- Geography
- 100+ Indian cities, metro and tier 2, plus global peer benchmarks
- Expert matching
- 24–48 hours from a confirmed brief
- Fieldwork window
- 5–10 business days for most interview and survey studies
- Core outputs
- Screened respondent profiles, recordings and transcripts, coded data tables and a cell and gene therapy readout with implications
- Regulatory context
- Work reflects advanced therapy regulatory pathways at FDA, EMA and CDSCO, chain-of-identity requirements and specialist centre accreditation.
Scope, sample and timings are confirmed in writing before fieldwork starts.
Why teams commission it
Decisions cell and gene therapy research supports
Each brief starts from the decision it has to inform, so the readout answers the question your team is actually facing.
Where to compete
Which cell and gene therapy segments, indications and accounts justify investment, and how treatment centres changes that picture.
What to build
Which features, claims and configurations stakeholders genuinely value, pressure-tested against outcomes-based pricing.
What it can be priced at
What buyers and payers will fund, the evidence they ask for first, and how manufacturing shapes willingness to pay.
How to launch
Sequencing, channel and messaging choices, grounded in how patient eligibility works in day-to-day practice.
Who to partner with
How potential partners, distributors and referral sources read your proposition in cell and gene therapy.
Where the risk sits
Competitive moves, switching triggers and the objections most likely to stall cell and gene therapy adoption.
Stakeholders
Who we reach in cell and gene therapy
We recruit the people who make and influence the decision — not only the easiest audience to find. Every expert is screened for recency of practice and conflicts of interest.
Treatment centres
- Transplant and cell therapy programme directors
- Treating haematologists and oncologists
- Apheresis and cell processing laboratory leads
- Cell therapy coordinators and specialist nurses
Supply and quality
- Manufacturing and CMC leads for advanced therapies
- Cold chain and courier logistics managers
- Quality assurance and qualified person roles
- Hospital pharmacy and chain-of-identity custodians
Access and eligibility
- Payer medical directors assessing one-time therapies
- HTA assessors and outcomes-based contracting leads
- Referring physicians identifying eligible patients
- Patient advocacy and travel support organisations
How it runs
A cell and gene therapy research programme, stage by stage
Senior researchers at our Pune, Maharashtra, India headquarters design, moderate and analyse every study.
- 01
Brief and research design
We turn your cell and gene therapy question into a screener, discussion guide or questionnaire, and agree the decision the readout has to support.
Scoped in writing
- 02
Recruit and screen
We identify cell and gene therapy stakeholders from our 5,000+ network, then screen for recency of practice, relevance and conflicts before anything is booked.
24–48 hours
- 03
Fieldwork
Expert calls, in-depth interviews or surveys run with senior moderation, covering treatment centres and the rest of your question set.
5–10 business days
- 04
Analysis and readout
Findings are coded, triangulated across audiences and delivered as a decision-ready report, with a live debrief for your team.
Report and debrief
Compliance
Standards every cell and gene therapy study runs under
Compliance is designed into the screener and the guide, not bolted on at the end.
Research codes
cell and gene therapy guides follow EphMRA, BHBIA and Insights Association standards, including adverse event and off-label handling.
Regulatory framing
Work reflects advanced therapy regulatory pathways at FDA, EMA and CDSCO, chain-of-identity requirements and specialist centre accreditation.
Data protection
Recruitment, transcripts and data files are handled under GDPR, HIPAA and India's DPDP Act, with pseudonymised outputs.
Conflict screening
Every expert is screened for employer restrictions, confidentiality obligations and conflicts of interest before a session is confirmed.
FAQs
Cell and Gene Therapy market research questions
What is cell and gene therapy market research?+
cell and gene therapy market research is primary research with the clinicians, buyers, payers and executives who shape the cell and gene therapy market. HealthcareMarketResearch covers treatment centres, outcomes-based pricing, manufacturing, patient eligibility through expert calls, in-depth interviews, surveys and advisory boards.
Who do you interview for cell and gene therapy studies?+
We recruit from a network of 5,000+ market researchers, KOLs and healthcare experts. For cell and gene therapy that typically means practising specialists, hospital pharmacists, procurement and value analysis leads, payers and former industry executives, all screened for recency and conflicts.
How quickly can a cell and gene therapy project start?+
Expert calls usually start within 24–48 hours of a confirmed brief. Surveys and qualitative studies typically go to field in 5–10 business days, depending on audience and sample size.
Which cell and gene therapy questions can you answer?+
Research on treatment centre readiness, logistics and payer models for advanced therapies. Common briefs cover treatment centres, outcomes-based pricing, manufacturing, patient eligibility, along with competitor positioning, pricing expectations and launch readiness.
Is your cell and gene therapy research compliant?+
Yes. Studies follow EphMRA, BHBIA and Insights Association guidelines, with adverse event reporting and off-label rules written into every guide. Work reflects advanced therapy regulatory pathways at FDA, EMA and CDSCO, chain-of-identity requirements and specialist centre accreditation.
Coverage
Where we run cell and gene therapy research in India
Studies are designed and analysed at our Pune, Maharashtra, India headquarters, with recruitment and fieldwork across 100+ Indian cities — metro, tier 2 and tier 3.
All industries
Explore the other 24 healthcare segments
Grouped by the kind of organisation or therapy area you work in, so you can find the neighbouring page quickly.
Life sciences companies
Therapy areas
Care delivery, payers and technology
Have a healthcare question that needs real answers?
Brief us today and talk to a verified expert this week.